For a patient aged 40-75 with LDL cholesterol 120 mg/dL and a 10-year PCE risk greater than 20%, what is the guideline-directed management?

For a patient aged 40-75 with LDL cholesterol 120 mg/dL and a 10-year PCE risk greater than 20%, what is the guideline-directed management?

• A. Heart healthy lifestyle and high-intensity statin
• B. Moderate-intensity statin therapy without calculating 10-year risk
• C. Ezetimibe alone
• D. No statin necessary

Answer: (A)

For high-risk primary prevention, the preferred move is to start high-intensity statin therapy alongside heart-healthy lifestyle changes. When 10-year ASCVD risk is over 20%, guidelines aim for a substantial LDL-C reduction (typically about ≥50%), often bringing LDL below about 70 mg/dL. In this patient, with LDL 120 mg/dL, beginning a high-intensity statin (such as atorvastatin 40–80 mg or rosuvastatin 20–40 mg) would markedly lower LDL and reduce ASCVD risk, while lifestyle measures (diet, exercise, smoking avoidance, weight management) support the overall benefit. A moderate-intensity statin would not achieve the recommended intensity for someone at this level of risk, so it’s not the best choice here. Using ezetimibe alone won’t adequately address the primary goal of initiating statin therapy in a high-risk patient, and no statin would be inappropriate given the elevated risk.

For high-risk primary prevention, the preferred move is to start high-intensity statin therapy alongside heart-healthy lifestyle changes. When 10-year ASCVD risk is over 20%, guidelines aim for a substantial LDL-C reduction (typically about ≥50%), often bringing LDL below about 70 mg/dL. In this patient, with LDL 120 mg/dL, beginning a high-intensity statin (such as atorvastatin 40–80 mg or rosuvastatin 20–40 mg) would markedly lower LDL and reduce ASCVD risk, while lifestyle measures (diet, exercise, smoking avoidance, weight management) support the overall benefit.

A moderate-intensity statin would not achieve the recommended intensity for someone at this level of risk, so it’s not the best choice here. Using ezetimibe alone won’t adequately address the primary goal of initiating statin therapy in a high-risk patient, and no statin would be inappropriate given the elevated risk.